Cardiology

Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.

Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.

Either one is fine – the point is to make sure the practice stays a step ahead of the next new drug class causing the problem.

Experts advise that primary care physicians give pause next time they treat a patient with unexplained dyspnea—could it be pulmonary hypertension?

Though the commonly accepted ratio is 3:1 women, longtime clinicians suggest PAH ratio is more likely closer to 4:1.

Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.

The ID CORE XT is the second molecular assay approved for use in transfusion medicine and the first to report results as genotypes.

Rivaroxaban (Xarelto) is now indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.

Using data registries from initial trials, companies such as Actelion will be looking to expand research beyond the first first or second year of care in patients with PAH.

Once physicians know if it's the cause of PAH or just simply an overlap, comorbidities have to be closely monitored as disease progression.

Why delving into the symptoms of the most at-need patients is critical for care.

The addition of a couple of new drug classes at the turn of the century have given clinicians the greenlight to stack therapies at initial treatment.

Now that real-world data registries are being compiled, the constriction-limiting drug class is now going through personalizations including new titration strategies.

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

A South Korea meta-analysis found that, similarly to C. difficile, tuberculosis risk could be limited by the lipid-lowering agent.

Instances of sexual harassment are associated with high blood pressure and poor sleep for women in midlife, while sexual assault is associated with poor mental health and sleep.

The association between moderate hyperbilirubinemia and childhood asthma and lack of association with higher bilirubin levels indicates the association is not causal.

It’s long been established that obesity can lead to asthma, but new research suggests asthma can also lead to obesity.

ECG Challenge: A 72-year-old woman is seen with generalized weakness x1week, acute altered mental status, and polydipsia. What's your ECG read?

The pulmonologist and senior medical advisor, American Lung Association, highlights the necessary steps of smoking cessation practices as well as the unknown surrounding e-cigarettes.

Have results of the COMPASS trial (rivaroxaban + aspirin in stable CAD) changed your opinion or clinical use of anticoagulants in patients post-ACS? If so, how?

The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.

The Eluvia stent system was approved based on data from the IMPERIAL non-inferiority trial, which compared Eluvia to Zilver PTX.